Page last updated: 2024-10-15

n(2)-(3-trifluoromethylphenyl)guanine

Cross-References

ID SourceID
PubMed CID135435057
CHEMBL ID405761
SCHEMBL ID8537131
MeSH IDM0179496

Synonyms (22)

Synonym
2-(3-(trifluoromethyl)anilino)-9h-purin-6-ol
2-[3-(trifluoromethyl)anilino]-9h-purin-6-ol
NCI60_029531
123994-68-3
n2-(m-trifluoromethylphenyl) guanine
2-[3-(trifluoromethyl)anilino]-1,9-dihydropurin-6-one
2-(3-trifluoromethyl-phenylamino)-1,9-dihydro-purin-6-one
nsc-682528
nsc682528
tmpg
CHEMBL405761 ,
bdbm50210810
n2-(3-trifluoromethylphenyl)guanine
2-[3-(trifluoromethyl)anilino]-3,7-dihydropurin-6-one
n(2)-(3-trifluoromethylphenyl)guanine
6h-purin-6-one, 1,7-dihydro-2-((3-(trifluoromethyl)phenyl)amino)-
SCHEMBL8537131
m-trifluoromethylphenylguanine
DTXSID00154178
2-{[3-(trifluoromethyl)phenyl]amino}-6,9-dihydro-1h-purin-6-one
2-[3-(trifluoromethyl)anilino]-1,7-dihydropurin-6-one
2-((3-(trifluoromethyl)phenyl)amino)-1h-purin-6(9h)-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase Macacine alphaherpesvirus 1IC50 (µMol)3.50000.15002.57504.2000AID326127
Thymidine kinaseHuman alphaherpesvirus 1 strain SC16IC50 (µMol)0.12570.10001.84917.9433AID210711; AID210716
Thymidine kinase Human alphaherpesvirus 2IC50 (µMol)0.10000.10000.84621.6000AID210714; AID210715
Thymidine kinaseHuman alphaherpesvirus 1 (Herpes simplex virus type 1)IC50 (µMol)0.15000.15004.81679.0000AID210696; AID210712
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID84399Inhibition against DNA-Dependent ATPase activity of HSV-1 helicase-primase in HSV-1-infected CV-1 cells1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Inhibition of herpes simplex virus type 1 helicase-primase by (dichloroanilino)purines and -pyrimidines.
AID210696Inhibition of HSV-1 thymidine kinase, 1 uM [3H]thymidine and ATP as phosphate donor1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases.
AID210714Inhibitory activity against HSV-2 thymidine kinase isolated from HeLa cells1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Quantitative structure-activity relationships of N2-phenylguanines as inhibitors of herpes simplex virus thymidine kinases.
AID14665Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases.
AID25177Half life in mice plasma was determined at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases.
AID210712Inhibition of TdR phosphorylation using thymidine kinase assay for herpes simplex virus type 11990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationships of N2-substituted guanines as inhibitors of HSV1 and HSV2 thymidine kinases.
AID22429Volume of distribution in mice plasma was determined at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases.
AID210711Inhibitory activity against HSV-1 thymidine kinase isolated from HeLa cells1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Quantitative structure-activity relationships of N2-phenylguanines as inhibitors of herpes simplex virus thymidine kinases.
AID14667Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases.
AID210716Inhibition of TdR phosphorylation using thymidine kinase assay for herpes simplex virus type 21990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Structure-activity relationships of N2-substituted guanines as inhibitors of HSV1 and HSV2 thymidine kinases.
AID210715Inhibition of HSV-2 thymidine kinase, 2 uM [3H]thymidine and ATP as phosphate donor1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases.
AID25174Half life in mice plasma was determined at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases.
AID326127Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (71.43)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]